Pesek M - Search Results

1

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala O, Pesek M, Finek J, Krejci J, Bortlicek Z, Benesova L, Minarik M. Fiala O, et al. Among authors: pesek m. Neoplasma. 2013;60(2):129-34. doi: 10.4149/neo_2013_017. Neoplasma. 2013. PMID: 23259780

2

Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.

Fiala O, Hosek P, Pesek M, Finek J, Racek J, Stehlik P, Sorejs O, Minarik M, Benesova L, Celer A, Nemcova I, Kucera R, Topolcan O. Fiala O, et al. Among authors: pesek m. Anticancer Res. 2017 Nov;37(11):6469-6476. doi: 10.21873/anticanres.12102. Anticancer Res. 2017. PMID: 29061834

3

Combination of Circulating Tumour DNA and ¹⁸F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study.

Fiala O, Baxa J, Svaton M, Benesova L, Ptackova R, Halkova T, Minarik M, Hosek P, Buresova M, Finek J, Ferda J, Pesek M. Fiala O, et al. Among authors: pesek m. Cancer Genomics Proteomics. 2022 Mar-Apr;19(2):270-281. doi: 10.21873/cgp.20319. Cancer Genomics Proteomics. 2022. PMID: 35181593 Free PMC article.

4

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. Fiala O, et al. Among authors: pesek m. Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10. Cancer Genet. 2013. PMID: 23313110

5

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Among authors: pesek m. Anticancer Res. 2013 Apr;33(4):1705-11. Anticancer Res. 2013. PMID: 23564819

6

Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Fiala O, et al. Among authors: pesek m. Anticancer Res. 2013 Aug;33(8):3397-402. Anticancer Res. 2013. PMID: 23898110

7

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O. Fiala O, et al. Among authors: pesek m. Anticancer Res. 2014 Jun;34(6):3205-10. Anticancer Res. 2014. PMID: 24922695

8

The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O. Fiala O, et al. Among authors: pesek m. Anticancer Res. 2014 Sep;34(9):5193-8. Anticancer Res. 2014. PMID: 25202114

9

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.

Svaton M, Fiala O, Pesek M, Bruha F, Mukensnabl P, Racek J, Minarik M, Bortlicek Z. Svaton M, et al. Among authors: pesek m. Anticancer Res. 2014 Dec;34(12):7461-5. Anticancer Res. 2014. PMID: 25503188

10

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Bortlicek Z, Topolcan O. Fiala O, et al. Among authors: pesek m. Tumour Biol. 2015 Aug;36(8):5801-5. doi: 10.1007/s13277-015-3249-x. Epub 2015 Feb 22. Tumour Biol. 2015. PMID: 25702091

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters